







RECEIVED

DEC 1 0 2001
PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent and Trademark drifted LHS. DEPARTMEND OF COMMERCE
U.S. Patent AND U.S. Pa

Substitute for Brand MASA/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a concessor or information unless it displays	a valid Civid Composijumicocy C
Application Number	09/928,122
Filing Date	August 10, 2001
First Named Inventor	J. Guy Breitenbucher et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1478

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Doo	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
RR	,	6,287,840	B1	Palmer, J. T. et al.	09-11-2001	435/219

FOREIGN PATENT DOCUMENTS

		Foreign	gn Patent Document Date of Public Of Cited Docu						
Examiner Initials	Cite No. ¹	Office ³	Number ⁴ Ki	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶	
RR		wo	95/23222	A1	Khepri Pharmaceuticals, Inc.	08-31-1995			
rr		wo	96/30353	A1	Arris Pharmaceutical Corporation	10-03-1996			
R		wo	97/40066	A1	Mass. Institute of Technology - Brigham & Women's Hospital	10-30-1997			
	<u> </u>							_	

Examiner Signature	Kanned	Date Considered 12-9-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





RECEIVED

DEC 1 0 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

*		
erwork Reduction Act of 1995, no persons are required to respond to	Approved tense through U.S. Patent and Trademark Office: U.S. DEPA a collection of information unless it displays a	RTMENT OF COMMERCE
рто	Application Number	09/928,122
	Filing Date	August 10, 2001
TION DISCLOSURE	First Named Inventor	J. Guy Breitenbucher et
THE DV ADDI ICANT		al
ENT BY APPLICANT	Group Art Unit	1614
e as many sheets as necessary)	Examiner Name	
Sheet 2 of 2	Attorney Docket Number	ORT-1478

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RR		PALMER, J. T. et al.; "Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors"; J. Med. Chem. (1995) 38(17):3193-3196	
RR		BROMME, D. et al.; "Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors"; Biochem. J. (1996) 315:85-89	
RR		MCGRATH, M.E. et al.: "Crystal structure of human cathepsin S"; Protein Science (1998) 7:1294-1302	
RR		NERENBERG, J. B. et al.; "Design and Synthesis of N-Alkylated Saccharins as Selective a-1A Adrenergic Receptor Antagonists"; Bioorg. Med. Chem. Lett. (1998) 8:2467-2472	
KR		HONEY, K. et al.; "Role of Lysosomal Cysteine Proteinases in Antigen Presentation to CD4 T Cells"; Inflammation Research (2001) Sup.3, Vol. 50, pS159 abstr. 10/01	
RR		LI, W. et al.; ""Tissue Specific Expression of Cathepsins and Antigen Presentation"; Inflammation Research (2001) Sup 3, Vol. 50 p S159 abstr. 10/02	
RR		MAGILL, C. et al.; "Cysteine Proteases in Antigen Presentation and Models of Inflammation"; Inflammation Research (2001) Sup 3, Vol 50, p S159, abstr. 10/03	
1805		ALLEN, E.M. et al.; "Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo"; Inflammation Research (2001) Sup 3, Vol. 50, p S159, abstr. 10/04	
RP		PODOLIN, P. L. et al.; "Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation in Vitro, and Reduces the Severity of Collagen-Induced Arthritis in Vivo"; Inflammation Research (2001) Sup. 3, Vol. 50, p S159, abstr. 10/05	
RP		SPERO, D. et al.; "Design and Synthesis of Novel Cathepsin S Inhibitors"; Inflammation Research (2001) Sup. 3, Vol. 50, p S206, abstr. 079	

	\sim /			
Examiner Signature	Kayrugh	Date Considered	12-9-03	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

DEC 0 8 5001 aperwork Reduction Act of 1995, no persons are required to respond to DEC 0 7 2001

Approved for use through Total 2005 ONE (08-00)
Approved for use through Total 2005 ONE (08-00)
Approved for use through Total 2005 ONE (08-00) U.S. Patent and Trademark Office: U.S. DEPARTMENT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a valid OMB control number.					
Application Number	09/928,122				
Filing Date	August 10, 2001				
First Named Inventor	J. Guy Breitenbucher et al.				
Group Art Unit	1614				
Examiner Name					
Attorney Docket Number	ORT-1478				

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Doo	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
RR		4,500,525		Winters , et al.	02-19-1985	514/210
RR		5,264,576		Shutske, et al.	11-23-1993	546/119
RR		5,776,718		Palmer, et al.	07-07-1998	435/23
RR		5,976,858		Palmer, et al.	11-02-1999	435/219
RR		6,030,946		Klaus, et al.	02-29-2000	514/12
					<u> </u>	
				·		
				TION DATENT DOOLINGUTO		

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docume	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number⁴ Kir	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear '	T ⁶
RR		EP .	382637	B1	Laboratorios del Dr. Esteve, S.A.	07-28-1993	·	
RR		EP	502786	B1	Laboratorios del Dr. Esteve, S.A.	04-24-1996		
RR		EP	655248	B1	Laboratorios del Dr. Esteve, S.A.	09-15-1999		
RR		wo	97/21439	A1	Laboratorios del Dr. Esteve, S.A.	06-19-1997		
RR		wo	99/24460	A2	Novartis AG	05-20-1999		
						1		
					·			

		,	
Examiner	1272	Date	
Signature	1 Carm	Considered	12-9-07
		10	


^{*}EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

conection of information unless it displays a valid Civis control number.					
Application Number	09/928,122				
Filing Date	August 10, 2001				
First Named Inventor	J. Guy Breitenbucher et				
	al.				
Group Art Unit	1614				
Examiner Name					
Attorney Docket Number	ORT-1478				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
RK		ANDRONATI, S.A. et al.: "Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and1H-indazoles and their affinity for benzodiazepine receptors"; Chemical Abstracts Number (CAN) 122:314528; (1994) 8:126-131	
mr		BROMME, D, et al.; "High level expression and crystallization of recombinant human cathepsin S"; Protein Science (1996) 5;789-791	
RR		KIRSCHKE, H. et al.; "Cathepsin S"; Handbook of Proteolytic Enzymes; Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624	
rr		NAKAGAWA, T.Y. et al.; "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice"; Immunity (1999) 10:207-217	
RR		RIESE, R.J. et al.; "Cathepsin S Activity Regulates Antigen Presentation and Immunity"; J. Clin. Invest. (1998) 101(11):2351-2363	
RR		SHI, G.P., et al.; "Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development"; Immunity (1999) 10:197-206	
RR		SINGH, P., et al.; "Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine"; Quant. StructAct. Relat. (1990) 9:29-32	
R		WINTERS, G. et al.; "Synthesis in Vitro [3H]Prazosin Displacement and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive"; J. Med. Chem. (1985) 28(7):934-940	
<u> </u>	-		

Examiner Signature	1 Carna	Date Considered	12-9-03
	7.507		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



JUL 2 5 2002



TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

luction Act of 1995, no persons are required to respond	to a collection of information unless it displays		
	Application Number	09/928,122	
	Filing Date	August 10, 2001	
N DISCLOSURE	First Named Inventor	J. Guy Breitenbucher	
BY APPLICANT	Group Art Unit	1614	
BT APPLICANT	Examiner Name	Not yet assigned	
y sheets as necessary)	Attorney Docket Number	ORT-1478	

		U.S. Patent Do	ocument			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
			-			
		•				
	ļ					
		0.				
				ON PATENT DOCUMENTS		

LLS PATENT DOCUMENTS

		Foreign	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number⁴ Ki	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
PR		GB	1489280	А	Chugai Pharmaceutical Co.	10-19-1977		
RP		EP	0254241	А	Yoshitomi Pharmaceutical	01-27-1988		
1818		JP	52014765	Α	Chugai Pharmaceutical Co., Ltd	02-03-1977		
RIT		JP	50116470	Α	Chugai Pharmaceutical Co., Ltd.	09-11-1975		
m		wo	9856785	Α	Sumitomo Pharmaceuticals Co., Ltd.	12-17-1998		
					V			

	\sim \sim			
Examiner Signature	1 Comment	Date Considered	12-9-03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/2002. OMB 666/6981
U.S. Patent and Trademark Office PLS DEPARTMENT OF COMMERCE o a collection of information unless it is black and in DMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a	ready principolitical number.
Application Number	109/908/1990/200
Filing Date	August 10, 260 (/)
First Named Inventor	J. Guy Breitenbucher
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	ORT-1478

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
RK		ANDRONATI, S., et al. "Synthesis of 3-aryl-1-piperzainyl)butyl in dazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors". Database CA 'Online! Chemical Abstracts Service, STN database accession no. 130:276243, XP002193795 abstract, (1999), 54(2), 99-101.	
R		FUJIMURA, Y. et al. "Indazole derivatives", Database CA 'Online! Chemical Abstracts Service, STN database accession no. 87:53281, XP002193796 abstract, (3 Feb. 1977) relating to JP 52014765 (Chugai Pharmaceutical Co., Ltd.)	
RN		FUJIMURA, Y., et al. "Indazole derivatives". Database CA 'Online! Chemical Abstracts Service, STN database accession no. 84:59450, XP002193797 abstract, (11 Sept. 1975) relating to JP 50116470 (Chugai Pharmaceutical Co., Ltd.)	
BR		NAKATSUKA, M. et al. "Preparation of pyrazole derivatives as immunosuppressants". Database CA 'Online! Chemical Abstracts Service, STN database accession no. 130:52417, XP002193692 abstract, (17 Dec. 1998) relating to WO9856785 (Sumitomo Pharmaceuticals Co., Ltd.)	

Examiner Signature	Raund	Date 12-9-03	
Signature		Considered	
* *			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

JUL 2 5 2002

1600/2900

SUBMISSION UNDER MPEP 609 D

Application Number	09/928_122
Filing Date	August () A 20 AITED
First Named Inventor	J. G. Breitenbucher
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	ORT-1478

		Page 1 of 1		Allomey	Dockerive	iiiibei	OK1-1476	
		U.S.	PATENT	DOCUMENT	rs			
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document		S. Patent Docu	ŀ	(ind Code ²	Pages, Colum where relevant prelevant figure	oassages (
	INO.					<u>```</u>		
	 					-		
-							 	
	 		_					
	<u> </u>							
				**				
								
						1		
	<u></u>	FOREIG	N PATE	NT DOCUME	NTS			
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreigi Office ³	n Patent Docur Number⁴	ment KindCode⁵	where re	Columns, Lines, elevant passages elevant figures appear	T ⁶
		***	1					
		•	 			•		
			-		_			·
<u> </u>			 					
			-			-		
	<u> </u>	OTHER PRIOR ART •	NON PATE	NT LITERATI	IRE DOCUME	NTS		
Examiner 's Initials*	Cite No.1	Include name of the author (in title of the item (book, magazin volume-issue number)	CAPITOL e, journal	LETTERS), , serial, symp	title of the ar	ticle (when log, etc.), d	late, page(s),	T ²
RP		PCT International Search Report, PCT	Γ/US01/25	289, April 12, 2	002.			

Examiner Signature	Date Considered	12-9-03
		